NeoImmuneTech, Inc.

70 articles about NeoImmuneTech, Inc.

• NeoImmuneTech Welcomes Two New Members to its Scientific Advisory Board

  7/26/2023

  NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announces the addition of two distinguished experts to its Scientific Advisory Board.

• NeoImmuneTech to Partner with U.S. National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) for Drug Development in Acute Radiation Syndrome (ARS)

  1/3/2023

  NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced an agreement with the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health, to develop NeoImmuneTech's main asset NT-I7, for the treatment of Acute Radiation Syndrome.

• New evidence of NeoImmuneTech's NT-I7 clinical efficacy in combination with pembrolizumab in relapsed/refractory (r/r) gastrointestinal tumors

  11/11/2022

  NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, presented new data from its phase 2a clinical study NIT-110, at the Society for Immunotherapy of Cancer 2022 annual meeting.

• NeoImmuneTech to Present First Data on NT-I7 (efineptakin alfa) in Combination with CAR-T tisagenlecleucel, at 2022 ASH Annual Meeting

  11/4/2022

  NeoImmuneTech, Inc. announced it will present first data from the combination of its main asset, NT-I7, with the chimeric antigen receptor T-cell tisagenlecleucel, at the American Society of Hematology annual meeting, to be held in New Orleans, Louisiana, December 10-13, 2022.

• NeoImmuneTech to Present New Advances on NT-I7 (efineptakin alfa) at 2022 SITC Annual Meeting

  10/5/2022

  NeoImmuneTech, Inc. today announced it will present development progress of its main asset, NT-I7 (efineptakin alfa), across five presentations at the Society for Immunotherapy of Cancer (SITC) annual meeting, to be held in Boston , November 8, 2022.

• NeoImmuneTech's NT-I7 Creates a More Immunogenic Tumor Microenvironment when Associated with Pembrolizumab

  9/12/2022

  NeoImmuneTech, Inc., a T cell-focused therapeutics company, presented data that suggests that NT-I7 plus pembrolizumab combination treatment enhances infiltration of PD-1+ T cells in cold tumors, at the European Society for Medical Oncology Congress in Paris, France, September 9-13, 2022.

• NeoImmuneTech Welcomes New Members to its Scientific Advisory Board

  8/8/2022

  NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announces the appointment of new members of its Scientific Advisory Board.

• FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech's NT-I7 for the treatment of Glioblastoma Multiforme

  7/13/2022

  NeoImmuneTech, Inc., a T cell-focused therapeutics company, announced that the U.S. Food and Drug Administration has granted NT-I7 Orphan Drug Designation for the treatment of Glioblastoma Multiforme.

• A Study in Nature Communications Reports that NeoImmuneTech's NT-I7 Enhances CAR-T Cell Expansion, Persistence and Anti-tumor Activity

  6/14/2022

  NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused therapeutics company, reported that Nature Communications (Impact Factor: 14.92) published the results of an in vivo study combining the long-acting human IL-7, NT-I7, with chimeric antigen receptor (CAR) T cells directed against CD19+ B cell lymphoma and acute myeloid leukemia.

• NeoImmuneTech to Present at Upcoming BIO International Convention

  6/13/2022

  NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announced that its Chief Business Officer, Sam Zhang , Ph.D., MBA, will present a company update at the upcoming BIO International Convention, to be held June 13-16 in San Diego, CA.

• NeoImmuneTech's Lead Asset NT-I7 (efineptakin alfa) Shows Preliminary Anticancer Activity in Combination with Check-Point Inhibitors

  6/6/2022

  NT-I7 plus pembrolizumab showed anti-tumor activity in heavily pretreated patients for whom checkpoint inhibitors are usually ineffective.

• NeoImmuneTech to Show Significant Advances on NT-I7 (efineptakin alfa) at 2022 ASCO Annual Meeting

  4/27/2022

  NeoImmuneTech, Inc. today announced it will present new clinical data for its lead asset NT-I7 (efineptakin alfa) across three presentations at the American Society of Clinical Oncology (ASCO) annual meeting, to be held in Chicago, June 3-7, 2022.

• NeoImmuneTech Demonstrates NT-I7’s Broad Combination Potential with Immune Checkpoint Inhibitors and Immunocytokine at AACR 2022

  4/13/2022

  Pre-clinical studies demonstrate NT-I7’s potential to enhance anti-tumor responses in combination with compounds targeting multiple biological pathways.

• 

  Money on the Move: March 9-15

  3/16/2022

  The companies that got money this week were the ones investing in ambitious, future-looking technologies, such as RNA genomics, biochips and antibody-drug conjugates. 

• NeoImmuneTech to Present Two Posters at American Association for Cancer Research Annual Meeting

  3/10/2022

  NeoImmuneTech, Inc. will be presented during poster sessions at the American Association for Cancer Research (AACR) annual meeting, to be held in New Orleans on April 8-13, 2022.

• NeoImmuneTech to Present at Upcoming Business Conferences

  2/9/2022

  NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced that its Chief Business Officer, Sam Zhang, Ph.D., MBA, will present at the upcoming BIO CEO and Investor Conference, to be held February 14-17 in New York, NY.

• NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) with PD-L1 Checkpoint Inhibitor in High-Risk Skin Cancers

  2/7/2022

  NeoImmuneTech, Inc. today announced that the first patient has been dosed in the Phase 2a portion of a study evaluating NT-I7 (efineptakin alfa).

• Preclinical Data on NT-I7 Published in Clinical Cancer Research

  1/24/2022

  NeoImmuneTech, Inc. today announced the publication of preclinical data evaluating the company’s lead asset NT-I7 (efineptakin alfa), a novel T cell amplifier, in mouse models of glioblastoma (GBM).

• NeoImmuneTech to Present at 2022 Biotech Showcase at J.P. Morgan Healthcare Conference

  1/5/2022

  NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that its Chief Business Officer, Sam Zhang, Ph.D., MBA, will present at the upcoming Biotech Showcase at J.P. Morgan Healthcare Conference, to be held in a virtual format from January 10-12 and 17-19.

• NeoImmuneTech Presents Phase 1 Study Data at Society for Neuro-Oncology Annual Meeting

  11/22/2021

  NeoImmuneTech, Inc. today presented data from Phase 1 of an ongoing study at the Society for Neuro-Oncology (SNO) annual meeting.